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Background. Sensory neuropathy (SN) is one of the most common AIDS-associated neurologic disorders especially in the era of
highly active antiretroviral therapy (HAART). The aim of this study was to determine the prevalence of SN among highly-active-
antiretroviral-therapy- (HAART-) experienced and HAART-na¨ ıve HIV-positive individuals and to investigate the relationship
to demographic, clinical, and laboratory factors. Methods. 323 patients with HIV infection (142 on HAART and 181 HAART
na¨ ıve) were enrolled in a cross-sectional neuropathy screening program. Data was collected using structured questionnaires which
contained the brief peripheral neuropathy screening tool of AIDS Clinical Trial Group protocol. Neuropathy was deﬁned by the
presence of at least 1 clinical sign in a distal, symmetrical pattern. Patients were classiﬁed as symptomatic if they described aching,
stabbing, or burning pain, paresthesia, or numbness in a similar distribution. Demographic, clinical, and laboratory details were
documented as risk factors. Result. The prevalence of sensory neuropathy was 39.0% (126/323), (of which 29/126 (23%)) were
symptomatic. Amongst those on HAART, 60/142 (42.3%) had SN compared to 66/181 (36.5%) HAART-na¨ ıve individuals (P =
0.29). On multivariate analyses, the independent associations with SN were increasing age (P = 0.03) and current exposure to
stavudine (P = 0.00). Gender (P = 0.99) height (P = 0.07) use of HAART (P = 0.50), duration of HAART treatment (P = 0.10),
and lower CD4 count (P = 0.12) were not associated with an increased SN risk. Conclusion. HIV SN remains common despite
improved immunologic function associated with HAART and decreased neurotoxic HAART use. In this cross-sectional analysis,
age and stavudine-based therapies were the independent risk factors.
1.Introduction
Peripheral neuropathy is common at all stages of human im-
munodeﬁciency virus (HIV) infection and causes consider-
able morbidity. The manifestations include focal mononeu-
ropathies (particularly cranial neuropathies) polyneuropa-
thies such as the inﬂammatory demyelinating polyneuropa-
thies (acute, subacute, and chronic subtypes), and sensory
neuropathy, which is the most common. In the pre-HAART
era, HIV sensory neuropathy (HIV-SN) was documented in
as high as 35% of patients with AIDS [1]. With the advent
of HAART, the prevalence has increased, a situation partially
attributable to the emergence of antiretroviral-induced toxic
neuropathy, particularly with the nucleoside analogue re-
verse transcriptase inhibitors (NRTIs) [2, 3].
Toxic or drug-induced sensory neuropathy is clinically
indistinguishable from sensory neuropathy of other aetiolo-
gies encountered in the setting of HIV. However, aetiological
clues include a recent history of drug implementation, im-
provement after drug withdrawal, and elevated serum lactate
concentration [4]. NRTIs used in antiretroviral therapy may
cause mitochondrial toxicity and dysfunction which leads
to the disturbance of the glucose metabolism, resulting in
an accumulation of lactate. The pathogenesis of sensory
neuropathy in HIV remains debatable, although the viral2 AIDS Research and Treatment
neurotoxicity hypothesis is favored. Indirect neuronal dam-
age is thought to occur as a consequence of immune acti-
vation that leads to the release of cytokines, free radicals and
lipid membranederivatives whicharepotentially neurotoxic.
In ARV-associated sensory neuropathy, mitochondrial dam-
age is implicated, with dysfunction attributed to the inhibi-
tion of DNA polymerase gamma, the enzyme responsible for
mitochondrial DNA replication. Chemotherapeutic agents
usedtotreatAIDS-relatedconditionssuchasvincristine,iso-
niazid,andhydroxyureacanalsocauseHIV-SN[5].Theclin-
ical presentation of HIVSN is marked by symmetrical often
burning painful paraesthesias in the feet, which may be so
severeastocausecontactallodyniaanddiﬃcultywithmobil-
ity. Involvement of the upper extremities and distal motor
weakness may occur later in the course. Diagnostic modal-
ities include the clinical examination and electrodiagnostic
evidence of predominantly axonal neuropathy [6]. Sural
nervebiopsyshowsdegenerationofmyelinatedandunmyeli-
nated axons with necrotizing vasculitis [7]. Skin biop-
sies with intraepidermal nerve ﬁbre density determination
can identify patients with sensory neuropathy and can be
used as an outcome measure. Treatment is largely unreward-
ing, and partial symptomatic relief is obtained from pain-
modifying agents such as nonsteroidal anti-inﬂammatory
drugs, antidepressants, anticonvulsants, or, in severe cases,
narcotic analgesics. ARV therapy may improve sensory
function in less advanced disease [8, 9].
This study was designed to estimate the burden of sen-
sory neuropathy in HIV/AIDS (acquired immunodeﬁciency
syndrome) patients and exploring the disease-related and
treatment-related determinants of its occurrence.
2. Methods
2.1. Study Population. This is a cross-sectional study con-
ducted at the HIV clinic of the Lagos State University Teach-
ing Hospital over a one-year period from January to Decem-
ber 2010. The study enrolled patients attending the HIV
clinic, who were at least 18 years and satisﬁed the World
Health Organization (WHO) clinical case deﬁnition for
HIV/AIDS. Eligibility criteria included the ability to undergo
a clinical interview consisting of a standardized neurological
evaluation for symptoms and signs of HIV-SN. Individuals
were excluded if they were on antituberculous medication,
had diabetes mellitus, chronic kidney disease, or active op-
portunistic infections or did not give consent. The hospital
ethics committee approved this research, and each partici-
pant gave informed consent.
2.2.Methods. Thedemographiccharacteristicsandinforma-
tionregardingHAARTusewereobtainedforallparticipants.
This was followed by the administration of the AIDS clinical
trial group (ACTG) Peripheral Neuropathy Screening Tool.
The instrument has been used widely in clinical trials and
encompasses both symptoms and clinical signs suggestive of
neuropathy. It has been shown in a large cohort of indi-
viduals with HIV infection to detect accurately those who
have the greatest degree of abnormality on formal sensory
threshold testing. HIV-SN was diagnosed in the presence of
at least 1 sign bilaterally (in consonance with the CHARTER
study, to enable higher sensitivity for detection of SN) [10].
Patients were classiﬁed as symptomatic if they described
aching,stabbing,orburningpain,paraesthesia,ornumbness
in a similar distribution. The presence of potential clinical
correlates and risk factors for HIV-SN such as patients
height, HAART use, including current exposure to speciﬁc
HIV-SN-associated drugs (stavudine-based HAART), alco-
hol abuse/dependence, and HIV disease marker (CD4 cell
count) were also evaluated. Prior exposure to stavudine-
based therapies was not ascertained.
2.3. Data Analysis. Data were analysed using SPSS version
17.0 statistical package. Continuous variablessuchas partici-
pant’s age, height, and CD4 cell count are presented as mean
± standard deviation (SD), and comparison between groups
was made using analysis of variance. Categorical variables
(e.g., gender, CD4 cell count category below or above 200
cells/mm3, HAART group) are presented as frequencies (%)
and group diﬀerences compared using nonparametric Yates’
corrected X2 test. Multivariate analysis was applied to deter-
mine the independent predictors of occurrence of HIV-SN.
3. Results
3.1. Demographic Characteristics. 323 participants compris-
ing218(67.5%)femalesand105(32.5%)maleswerestudied.
97 (68.3%) females and 45 (31.7%) males were on HAART
(total 142) whilst 121 (66.9%) females and 60 (33.1%) males
were HAART na¨ ıve (total 181). There was no signiﬁcant
gender diﬀerence between the groups (X2 = 0.77; P = 0.81).
The mean age of the HAART-experienced group was 38.3 ±
10.8 (median 35.5), while that of the HAART-na¨ ıve controls
was35.5±8.7(P = 0.009).MeanCD4cellcount(cells/mm3)
was 246.1 ±152.2 in the HAART group and 189.7 ±150.1i n
the HAART-na¨ ıve group (P = 0.001) Table 1. The HAART
group was characterized by speciﬁc drug combination into
two groups: stavudine based (12/142) and non-stavudine
based (130/142). The duration of exposure to HAART was
1–48 months, with a mean of 16.4 ± 10.7 months (median
17.0 months).
3.2. Prevalence and Risk Factors of HIV-Associated Sensory
Neuropathy (HIV-SN). HIV-associated sensory neuropathy,
deﬁned as the presence of at least 1 abnormal neuropathy
sign, was present in 126 (39.0%) of the entire cohort
(N = 323). Of the patients with HIV-SN, 29 (23.0%) were
symptomatic, while 97 (77.0%) were asymptomatic. The
frequency of HIV-SN in the HAART-experienced group was
42.3% (60/142), whilst it was 36.5% (66/181) in the HAART-
na¨ ıve group (P = 0.29). The clinical characteristics of the
HIV/AIDSpatientswithandwithoutsensoryneuropathyare
shown in Table 2.
The determinants of occurrence of HIV-SN were
explored using variables obtained in this study. Speciﬁcally,
the eﬀe c to fa g eg r o u p( a b o v e4 0y e a r s ) ,g e n d e r ,h e i g h t
(above 1.7m), HAART use, duration of HAART use (aboveAIDS Research and Treatment 3
Table 1: Demographic and clinical characteristics of 323 participants in the HIV-SN study.
Variables All
N = 323
HAART treated
N = 142
HAART na¨ ıve
N = 181 P value
Male 105 (32.5%) 45 (31.7%) 60 (33.1%) 0.81
Female 218 (67.5%) 97 (68.3%) 121 (66.9%)
Mean age ± SD (years) 36.7 ±9.83 8 .3 ±10.83 5 .5 ±8.7 0.009
Age category >40 years 9 (30.0%) 51 (52.6%) 48 (49.5%) 0.09
Mean height ± SD, metres 1.61 ±0.08 1.59 ±0.07 1.62 ±0.09 0.000
Height category >1.7 metres 44 (13.6%) 4 (2.8%) 40 (22.1%) 0.000
Mean CD4 count ± SD, cells/mm3 214.5 ±153.4 246.1 ±152.2 189.7 ±150.1 0.001
CD4 count >200, cells/mm3 147 (45.5%) 81 (57.0%) 66 (36.5%) 0.000
CD4 count ≤200, cells/mm3 176 (54.5%) 61 (43.0%) 115 (63.5%)
Table 2: Relationship between demographic and clinical variables and the occurrence of HIV-sensory neuropathy.
Variables SN present
N = 126
SN absent
N = 197 P value
Mean age ± SD, years 38.2 ±10.63 5 .8 ±9.10 . 0 3
Male (N = 105) 48 (45.7%) 57 (54.3%) 0.09
Female (N = 218) 78 (35.8%) 140 (64.2%)
Mean height ± SD, metres 1.62 ±0.08 1.60 ±0.08 0.15
HAART treated (N = 142) 60 (42.3%) 82 (57.7%) 0.29
HAART na¨ ıve (N = 181) 66 (36.5%) 115 (63.5%)
Mean duration of HAART ± SD,
months∗ 15.9 ±9.41 6 .9 ±11.60 . 5 9
Stavudine-based HAART (N = 12) 10 (83.3%) 2 (16.7%) 0.003∗∗
Non-stavudine-based HAART (N = 130) 50 (38.5%) 80 (61.5%)
Mean CD4 count ± SD, cells/mm3 180.9 ±138.2 236.0 ±159.0 0.002
Median CD4 count ± SD, cells/mm3 165.5 185.0
CD4 count ≤ 200, cells/mm3 (N = 176) 74 (42.0%) 102 (58.0%) 0.22
CD4 count >200, cells/mm3 (N = 147) 52 (35.4%) 95 (64.6%)
∗Duration of therapy for the 142 participants on HAART therapy. ∗∗Fisher’s exact P value.
12months),andARVcategory(stavudine ornon-stavudine-
based therapy) was evaluated in multivariate logistic regres-
sion analysis. Age above 40 years (P = 0.03) and stavudine-
based ARV use (P = 0.00) were signiﬁcantly independently
associated with the occurrence of sensory neuropathy, the
strongest determinant being the latter (Table 3).
4. Discussion
This cross-sectional study on the burden of HIV-sensory
neuropathy has added to existing body of evidence that
HIV-SN occurs frequently in people with HIV/AIDS, with
a frequency of 39% overall and 36.5% on cases on HAART.
Recent estimates of HIV-SN prevalence among cohorts with
access to HAART ranges from 20 to 50% irrespective of
whether there is additional risk such is conferred by the use
of established neurotoxic antiretroviral drugs [11, 12]. Also,
available evidence suggests that HIV-SN prevalence remains
high among HAART-treated patients, even in regions where
known neurotoxic antiretroviral drugs such as stavudine are
no longer commonly used [12]. In this study, only 12/323
cases were on stavudine-based HAART suggesting that other
risk factors should be considered and the aetiology of HIV-
SN is clearly beyond that attributable to use of neurotoxic
HAART. Host genotype has been associated with HIV-SN
risk among neurotoxic HAART-exposed patients in several
groups. Consistent with pathogenic mechanisms of HIV-
SN, the associations include mitochondrial haplogroups
and genes associated with inﬂammation. Associations with
hemochromatosis gene polymorphisms have also been re-
ported [13, 14].
Considering the persisting risk of HIV-SN despite opti-
mizing therapy for HIV, we explored the determinants of
occurrence of HIV-SN and found one nonmodiﬁable inde-
pendent predictor, that is, advancing age above 40 years, and
most importantly, a modiﬁable risk factor, that is, the use of4 AIDS Research and Treatment
Table 3: Determinants of occurrence of HIV-sensory neuropathy using multivariate regression analysis.
Variable B Standard error P value
Age (< or ≥40 yrs) −.566 .271 0.03∗
Gender −.004 .293 0.99
Height (< or ≥1.7m) .627 .353 0.07
CD4 category (≤ or >200) .384 .246 0.12
HAART use .257 .389 0.50
HAART type, (stavudine/Non-stavudine-based) −2.525 .833 0.00∗
Duration of HAART use, (< or >12 months) .666 .409 0.10
∗Signiﬁcantly associated with the presence of HIV-SN.
stavudine-based therapy. Gender, height, lower CD4 count,
use of HAART, and duration on HAART were not associated
with increased risk. Ellis in the Central Nervous System HIV
Antiretroviral Therapy Eﬀects Research (CHARTER) study
[10] had documented lower nadir CD4 count and the use
of HAART, in addition to advancing age, as risk factors. He
speculated that HAART is neurotoxic as it was associated
with higher SN prevalence. Maritz and colleagues also doc-
umented use of HAART in addition to age as risk factors of
SN.
Age has remained a consistent independent risk factor
in almost every published cohort, both before and after the
introduction of HAART [15–17]. This is consistent with
the known vulnerability of the aging peripheral nervous
system to most types of polyneuropathies, HIV-SN inclusive.
Height has also been identiﬁed as a risk factor for sensory
neuropathy in HIV infection on HAART. The pathology
involves a length-dependent degeneration of both small and
large peripheral nerve ﬁbers making taller individuals more
prone to the development of SN. Cherry et al. [18]h a d
documented that the risk of HIV-SN was 65% higher among
the older (>40 years) and taller (>170cm) HIV patients
exposed to stavudine. They proposed that age and height
measurements represent an eﬀective way of identifying
individuals at higher risk for neuropathy and prioritizing
them to alternative HAART therapy rather than neurotoxic
HAART. Height was not found to be an independent risk
factor in this study probably due to the small number of
patients that were above 1.7m.
Previously reported literature assessing immune status
and HIV-SN is mixed, with some reports linking neuropathy
to increased viral load levels, while others have reported no
relationship. Several studies from the highly active antiretro-
viral therapy (HAART) era show a lack of association be-
tween distal painful sensorimotor polyneuropathy and the
degree of immunosuppression, including low CD4 counts
a n dh i g hH I Vv i r a ll o a d[ 19, 20]. Morgello and colleagues
speculate that this diﬀerence in ﬁndings may relate to a dif-
ference in patient populations. Other reasons may include
residualaxonalinjuryevenwithrestorationofimmunefunc-
tion, immune reconstitution disorders or even the presence
ofotherconfoundingneurotoxinssuchasnutritionalorvita-
min deﬁciencies. Also the association between neuropathic
pain and a higher CD4 nadir may suggest that a functional
immune system may contribute to the stimulation of pain.
Limitations of our study include a cross-sectional design
as a longitudinal follow-up would provide further insight
into the incidence of HIV-SN in Nigerians. Furthermore, the
nonavailability of electrophysiological studies limited diag-
nostic accuracy.
5. Conclusion
This study has conﬁrmed the high prevalence of SN in
HIV/AIDSpatientsonHAART.SNpersistsdespiteimproved
immunologic function associated with HAART and de-
creased neurotoxic HAART use. With these high prevalent
rates and majority experiencing debilitating neuropathic
pain, HIV-SN represents a huge and potentially worsening
source of world morbidity. There is need to develop more
eﬀective preventative strategies and treatments to control the
symptoms associated with existing cases of HIV-SN.
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